23rd Annual Fanconi Anemia Research Fund Scientific Symposium

描述（由申请人提供）： 范可尼贫血（FA）是一种罕见的遗传性疾病，其特征是骨髓衰竭、发育异常、骨髓增生异常（MDS）、急性非淋巴细胞白血病（AML）、实体瘤和对交联剂的细胞超敏反应。范可尼贫血的一个独特特征是在生命早期发生通常仅在老年人群中发现的特定上皮和造血恶性肿瘤。这些蛋白质的功能在很大程度上是未知的，但许多蛋白质彼此形成复合物，在一个典型的“途径”中，11种已知的范可尼贫血蛋白中的8种结合在一起形成复合物，并与一种不在“核心”复合物中的蛋白质FANCD 2结合。有体外和体内证据表明，至少一些FA蛋白也通过与信号分子形成复合物来促进造血细胞中的存活信号通路。干细胞移植是符合条件的骨髓衰竭患者的治疗选择。骨髓衰竭的幸存者最终面临着极高的发展鳞状细胞癌的风险。这种疾病是一个理想的候选基因治疗，因为固有的选择性补充干细胞。正在开发的广泛证据表明，FA信号通路的功能障碍可以发展为非范科尼患者中产生的肿瘤细胞中的体细胞变化（表观遗传和遗传），并且这种体细胞变化的后果抑制了自我复制潜力并增强了祖细胞池的衰老。一年一度的范科尼贫血研究基金科学研讨会是一个为期三天的会议，包括选择邀请演讲和大约35-45口头摘要介绍（从摘要中选择）在一个单一的轨道格式。研讨会汇集了来自世界各地的领先研究人员和医生以及年轻的研究人员，研究生和研究生，讨论这种罕见疾病的所有基础，转化和临床研究方面。范科尼贫血研究基金积极鼓励和支持学生和初级研究人员的出席和提交。会议为研究人员提供了一个独特的机会，以交叉施肥和开发跨学科的研究项目。这些数据不仅将与所有研究人员免费共享，而且还将通过在线生物信息工具GeneSifter访问这些文件。本申请寻求对定于2011年10月在西班牙巴塞罗那举行的这次会议的部分支持。

DESCRIPTION (provided by applicant): 23rd Annual Fanconi Anemia Research Fund Scientific Symposium Fanconi anemia (FA) is a rare hereditary disease characterized by bone marrow failure, developmental anomalies, a high incidence of myelodysplasia (MDS), acute non-lymphocytic leukemia (AML), solid tumors, and cellular hypersensitivity to cross-linking agents. A unique feature of Fanconi anemia is the development, in early life, of specific epithelial and hematopoietic malignancies usually found only in aging populations. The function of the proteins is largely unknown but many form complexes with each other and in one canonical "pathway," eight of the eleven known Fanconi anemia proteins bind together in a complex and monoubiquitinate FANCD2, one of the proteins not in the "core" complex. There is in vitro and in vivo evidence that at least some of the FA proteins also promote survival signaling pathways in hematopoietic cells by forming complexes with signaling molecules. Stem cell transplantation is the treatment of choice for eligible patients with bone marrow failure. Survivors of bone marrow failure ultimately face an extremely high risk of developing squamous cell cancers. The disease is an ideal candidate for gene therapy because of the inherent selectability of complemented stem cells. Broad evidence is being developed that dysfunction of the FA signaling pathways can develop as somatic changes (epigenetic and genetic) in neoplastic cells arising in non-Fanconi patients and that the consequences of such somatic changes suppress self-replicative potential and enhance senescence in progenitor cell pools. The annual Fanconi Anemia Research Fund Scientific Symposium is a three-day conference comprised of select invited presentations and approximately 35-45 oral abstract presentations (to be chosen from a call for abstracts) in a single-track format. The Symposium brings together leading researchers and physicians as well as young investigators, graduate and post-graduate students from around the world to discuss all basic, translational, and clinical research aspects of this rare disease. The Fanconi Anemia Research Fund actively encourages and supports attendance and submissions by students and junior investigators. The meeting provides a unique opportunity for investigators to cross-fertilize and develop interdisciplinary research projects. Not only will the data be shared freely with all investigators, the files will be made accessible through GeneSifter, an online bio-information tool. This application seeks partial support for this meeting, scheduled to be held in Barcelona, Spain in October 2011.